May #123 : Women on Top - by Rebecca Minnich

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents
One Tough Pirate

Seeing the Future

Mentors-May 2006

Medicine Men

Custom Care

Early Birds

Simply Irresistible

The Topic of Cancer

Sow Your Oats

Trainer’s Bench-May 2006

Hustle and Flow

Animal Attraction

Purrrfect Health

Women on Top

PEP Rally

POZ Personals Catch of the Month-May 2006

First Aid for Your Medicaid

Shall We Dance?

A Will & Grace-full Exit?

Ratings for a Serial Virus

Squeaky Clean?

Prescription For Change

Bono’s Red Alert

One Hot ASO

Banned Aid

It’s Not You; It’s Me

Near Dead Again

Editor's Letter-May 2006

Mailbox-May 2006

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

May 2006

Women on Top

by Rebecca Minnich

An HIV gel slides toward FDA approval

Microbicides would allow ladies to control their own sexual safety, without depending on men to wear a condom and avoid unsafe sex on the side. Though activists have pushed the products as a funding and research priority since 1990, not one has been approved—prompting charges that the medical establishment ignores women’s safety. (It’s an equal-opportunity offender: No gels for men exist either.) In January, however, the Food and Drug Administration put the HIV-blocking vaginal microbicide VivaGel on what it dubs its “fast track” to approval. Fast-track status means that the FDA will speed the review of all findings. It doesn’t mean more funds will be pumped into VivaGel’s development. The manufacturer, Starpharma, hopes for approval as early as 2008. Anna Forbes from the Global Campaign for Microbicides, says, “2008 is very optimistic. VivaGel hasn’t entered Phase III [human] trials yet.”

VivaGel is the second microbicide to be fast tracked (the first was in 2003 and is still in Phase III  trials), and dozens more are creeping up the pipeline. “It’s good news, but we need to move the whole pipeline forward,” Forbes adds. “Nobody knows which one is going to work.”

Global funds for microbicides more than doubled from $66 million in 2000 to $163 million in 2005. “We had several microbicides in advanced trials, and people noticed that women now make up the majority of new infections. It caused a shift in public discourse,” says Forbes. “But we still have only half the funding we need.” The International Partnership for Microbicides recently received a $30 million grant, but the organization’s Joseph Romano, MD, says it needs $100 million more by 2007 to get even one microbicide through Phase III trials. And then, hopefully, fast track a sexual revolution.     

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.